[Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis].
We treated two chronic phase chronic myelogenous leukemia patients with imatinib mesylate. Hematological complete remission and significant regression of bone marrow fibrosis were observed in both patients. The large amount of TGF-beta produced by increased bone marrow megakaryocytes might have caused the myelofibrosis, and it was revealed that imatinib mesylate brought about regression of the myelofibrosis by reducing the number of megakaryocytes in both patients.
Takahari
Daisuke
D
Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine.
Matsunaga
Takuya
T
Fujimi
Akihito
A
Kikuchi
Tomoki
T
Seki
Ryoya
R
Tanaka
Ikuta
I
Takemoto
Naofumi
N
Akiyama
Takehide
T
Sato
Tsutomu
T
Terui
Takeshi
T
Kogawa
Katsuhisa
K
Kato
Junji
J
Kura
Toshiro
T
Maeda
Takeshi
T
Niitsu
Yoshiro
Y
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate